Skip to main content
Contact Us
Subscribe
E-Edition
47°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arrowhead Pharmaceuticals, Inc.
< Previous
1
2
3
4
Next >
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
January 17, 2025
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
December 23, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 19, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
December 11, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
December 03, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
December 02, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
November 26, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
November 26, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
November 18, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
November 18, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
November 05, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
November 04, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
November 01, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 14, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
September 23, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
September 02, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
August 21, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
August 14, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
August 08, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
August 08, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 29, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
July 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
June 25, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
June 24, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
June 03, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
May 31, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
May 29, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
May 28, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
May 20, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
May 09, 2024
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ARWR
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.